We are live on ! Find out more
ELVN icon

Enliven Therapeutics
ELVN

31 hedge funds and large institutions have $8.78M invested in Enliven Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

19% more funds holding

Funds holding: 26 → 31 (+5)

13% more capital invested

Capital invested by funds: $7.76M → $8.78M (+$1.02M)

2.29% less ownership

Funds ownership: 10.12% → 7.83% (-2.3%)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

66% less call options, than puts

Call options by funds: $939K | Put options by funds: $2.73M

Holders
31
Holders Change
+5
Holders Change %
+19.23%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
4
Reduced
7
Closed
7
Calls
$939K
Puts
$2.73M
Net Calls
-$1.79M
Net Calls Change
-$1.79M

Top Buyers

Rank Fund Capital Flow
1
JC
JBF Capital
Colorado
+$310K
2
CM
Caption Management
Oklahoma
+$251K
3
JG
Jefferies Group
New York
+$154K
4
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$146K
5
Citadel Advisors
Citadel Advisors
Florida
+$141K

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$1.23M
2
LPC
Lion Point Capital
New York
-$1.14M
3
Goldman Sachs
Goldman Sachs
New York
-$1.06M
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$223K
5
Two Sigma Investments
Two Sigma Investments
New York
-$145K
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
1
Woodline Partners
California
$1.98M -$125K -21,222 -9%
RSCM
2
Rock Springs Capital Management
Maryland
$1.92M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$751K -$115K -19,549 -19%
Vanguard Group
4
Vanguard Group
Pennsylvania
$693K +$56.8K +9,617 +14%
JC
5
JBF Capital
Colorado
$479K +$310K +52,500 New
CM
6
Caption Management
Oklahoma
$388K +$251K +42,500 New
BCM
7
Bridgeway Capital Management
Texas
$288K – – –
BlackRock
8
BlackRock
New York
$252K -$19.4K -3,291 -11%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$239K +$72.8K +12,334 +89%
JG
10
Jefferies Group
New York
$238K +$154K +26,075 New
Parallax Volatility Advisers
11
Parallax Volatility Advisers
California
$226K +$146K +24,775 New
Citadel Advisors
12
Citadel Advisors
Florida
$217K +$141K +23,836 New
Group One Trading
13
Group One Trading
Illinois
$212K +$137K +23,249 New
Morgan Stanley
14
Morgan Stanley
New York
$140K -$45.5K -7,708 -33%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$120K – – –
MAM
16
Marquette Asset Management
Minnesota
$118K -$39.9K -6,753 -34%
MA
17
MYDA Advisors
New York
$91K +$59K +10,000 New
AFM
18
Anson Funds Management
Texas
$65K +$41.8K +7,089 New
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$64K +$41.7K +7,066 New
Tudor Investment Corp
20
Tudor Investment Corp
Connecticut
$56K -$40.4K -6,847 -53%
GVAG
21
Great Valley Advisor Group
Delaware
$48K – – –
State Street
22
State Street
Massachusetts
$48K – – –
Rockefeller Capital Management
23
Rockefeller Capital Management
New York
$41K – – –
HF
24
HRT Financial
New York
$36K +$23.3K +3,948 New
Northern Trust
25
Northern Trust
Illinois
$35K – – –
1
2

ELVN Hedge Fund Activity: Q3 2022 in Review

31 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q3 2022, worth a combined $8.78M — up 13% from $7.76M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ELVN positions and 7 closed out — a net gain of 5 holders — while 4 added to existing stakes and 7 trimmed.

The largest buyer was JBF Capital, opening a new position worth an estimated $310K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.23M sold.

  • 31 institutional investors held Enliven Therapeutics (ELVN) as of Q3 2022, up from 26 in Q2 2022.
  • Funds reported $8.78M of Enliven Therapeutics stock for Q3 2022, up 13% quarter-over-quarter.
  • 12 funds opened new Enliven Therapeutics positions in Q3 2022 and 7 closed out, a net change of +5 holders.
  • The largest Enliven Therapeutics buyer in Q3 2022 was JBF Capital, an estimated $310K added.
  • The largest Enliven Therapeutics seller in Q3 2022 was NEA Management Company, an estimated $1.23M sold.

Based on aggregated 13F filings for Q3 2022.